UNIVERSITY OF HEALTH SCIENCES, DİYARBAKIR GAZİ YAŞARGİL HEALTH RESEARCH CENTER, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, HEMATOLOGY
Auto-generated profile, based on publicly available information
Şengül Baran Yerlikaya
UNIVERSITY OF HEALTH SCIENCES, DİYARBAKIR GAZİ YAŞARGİL HEALTH RESEARCH CENTER, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, HEMATOLOGY
Background: The prognostic significance of the Endothelial Activation and Stress Index (EASIX) score has been demonstrated in several hematologic malignancies. This study aimed to evaluate the predictive value of the EASIX score for survival outcomes in patients with advanced-stage classical Hodgkin Lymphoma (cHL).Material and Method: This retrospective study included patients with advanced-stage cHL (stage IIB–IV) who received ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as first-line therapy. EASIX scores were calculated at diagnosis using the formula: serum creatinine (mg/dL) × LDH (U/L) / platelet count (10^9/L).Results: A total of 85 patients were analyzed. The median age was 36 years, and 61.2% were male. Based on the optimal ROC-derived cutoff value (0.66), 47 patients (55%) were classified into the low-EASIX group and 38 patients (45%) into the high-EASIX group. Progression-free survival (PFS) did not differ significantly between the groups (p = 0.405), and the median PFS was not reached in either group. Similarly, no significant difference in overall survival (OS) was observed (p = 0.295). The median OS for the high-EASIX group was 141.2 months, while it was not reached in the low-EASIX group.Conclusion: The EASIX score was not associated with survival outcomes in patients with advanced-stage cHL. Further studies with larger cohorts are needed to clarify its prognostic role in this setting.